Replimune Group (REPL) Stock Forecast & Price Target

Compare

301 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

REPL Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Replimune

Group

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

REPL Stock 12 Month Forecast

Average Price Target

$22.00

▲(100.55%Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $22.00 with a high forecast of $31.00 and a low forecast of $16.00. The average price target represents a 100.55% change from the last price of $10.97.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","11":"$11","18":"$18","25":"$25","32":"$32"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,11,18,25,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.15,10.830769230769231,12.511538461538462,14.192307692307693,15.873076923076923,17.553846153846152,19.234615384615385,20.915384615384617,22.596153846153847,24.276923076923076,25.957692307692305,27.63846153846154,29.31923076923077,{"y":31,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.15,10.138461538461538,11.126923076923077,12.115384615384615,13.103846153846154,14.092307692307692,15.080769230769231,16.06923076923077,17.057692307692307,18.046153846153846,19.034615384615385,20.02307692307692,21.01153846153846,{"y":22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.15,9.676923076923078,10.203846153846154,10.730769230769232,11.257692307692308,11.784615384615385,12.311538461538461,12.838461538461539,13.365384615384617,13.892307692307693,14.419230769230769,14.946153846153846,15.473076923076924,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.73,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.48,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.27,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.36,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.22,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.17,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.9,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.55,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.11,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.98,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.64,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.57,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$31.00

Average Price Target$22.00

Lowest Price Target$16.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Robert BurnsH.C. Wainwright

H.C. Wainwright

$22

Buy

100.55%

Upside

Reiterated

07/07/25

H.C. Wainwright Remains a Buy on Replimune Group (REPL)

Robert DriscollWedbush

Wedbush

$19

Buy

73.20%

Upside

Reiterated

06/25/25

Wedbush Keeps Their Buy Rating on Replimune Group (REPL)

Peter LawsonBarclays

Barclays

$17

Buy

54.97%

Upside

Reiterated

06/25/25

Replimune Group (REPL) Receives a Buy from Barclays

Li WatsekCantor Fitzgerald

Cantor Fitzgerald

―

Buy

―

Reiterated

06/25/25

Cantor Fitzgerald Keeps Their Buy Rating on Replimune Group (REPL)

Evan SeigermanBMO Capital

BMO Capital

$27

Buy

146.13%

Upside

Reiterated

06/24/25

Optimistic Buy Rating for Replimune Group: Strategic Positioning and Growth Potential Highlighted by TUDRIQEV's Market Readiness and Expansion Opportunities

Jonathan ChangLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/24/25

Replimune Group's Promising Future: Buy Rating Backed by Strategic Launch Plans and Positive Clinical DataWe continue to believe the clinical data support the potential approval of RP1 in this setting. A key focus of the Investor Day was a discussion of the RP1 commercial efforts ahead of the potential approval of RP1 + nivolumab for anti-PD-1 failed melanoma (PDUFA date 07/22/25), which we believe will be the next key catalyst for the stock. Overall, we continue to view REPL favorably given the positive IGNYTE data and the potential approval of RP1 in anti-PD-1-failed melanoma. Reiterate OP.

Roger SongJefferies

Jefferies

$19→$31

Buy

182.59%

Upside

Reiterated

06/05/25

Replimune Group (REPL) Gets a Buy from Jefferies

Anupam RamaJ.P. Morgan

J.P. Morgan

$16

Buy

45.85%

Upside

Reiterated

06/03/25

J.P. Morgan Sticks to Their Buy Rating for Replimune Group (REPL)

Allison BratzelPiper Sandler

Piper Sandler

$14→$22

Buy

100.55%

Upside

Reiterated

06/02/25

Replimune price target raised to $22 from $14 at Piper SandlerReplimune price target raised to $22 from $14 at Piper Sandler

Benjamin Paluch CFARoth MKM

Roth MKM

$17

Buy

54.97%

Upside

Reiterated

09/09/24

Roth/MKM reiterates Buy Rating on Replimune Group (REPL)Roth/MKM analyst Ben Paluch reiterated a Buy rating and $17.00 price target on Replimune Group (NASDAQ: REPL).

Anthony ButlerRodman & Renshaw

Rodman & Renshaw

$12

Buy

9.39%

Upside

Initiated

08/08/24

Replimune Group initiated with a Buy at Rodman & RenshawReplimune Group initiated with a Buy at Rodman & Renshaw

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Robert BurnsH.C. Wainwright

H.C. Wainwright

$22

Buy

100.55%

Upside

Reiterated

07/07/25

H.C. Wainwright Remains a Buy on Replimune Group (REPL)

Robert DriscollWedbush

Wedbush

$19

Buy

73.20%

Upside

Reiterated

06/25/25

Wedbush Keeps Their Buy Rating on Replimune Group (REPL)

Peter LawsonBarclays

Barclays

$17

Buy

54.97%

Upside

Reiterated

06/25/25

Replimune Group (REPL) Receives a Buy from Barclays

Li WatsekCantor Fitzgerald

Cantor Fitzgerald

―

Buy

―

Reiterated

06/25/25

Cantor Fitzgerald Keeps Their Buy Rating on Replimune Group (REPL)

Evan SeigermanBMO Capital

BMO Capital

$27

Buy

146.13%

Upside

Reiterated

06/24/25

Optimistic Buy Rating for Replimune Group: Strategic Positioning and Growth Potential Highlighted by TUDRIQEV's Market Readiness and Expansion Opportunities

Jonathan ChangLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

06/24/25

Roger SongJefferies

Jefferies

$19→$31

Buy

182.59%

Upside

Reiterated

06/05/25

Replimune Group (REPL) Gets a Buy from Jefferies

Anupam RamaJ.P. Morgan

J.P. Morgan

$16

Buy

45.85%

Upside

Reiterated

06/03/25

J.P. Morgan Sticks to Their Buy Rating for Replimune Group (REPL)

Allison BratzelPiper Sandler

Piper Sandler

$14→$22

Buy

100.55%

Upside

Reiterated

06/02/25

Replimune price target raised to $22 from $14 at Piper SandlerReplimune price target raised to $22 from $14 at Piper Sandler

Benjamin Paluch CFARoth MKM

Roth MKM

$17

Buy

54.97%

Upside

Reiterated

09/09/24

Roth/MKM reiterates Buy Rating on Replimune Group (REPL)Roth/MKM analyst Ben Paluch reiterated a Buy rating and $17.00 price target on Replimune Group (NASDAQ: REPL).

Anthony ButlerRodman & Renshaw

Rodman & Renshaw

$12

Buy

9.39%

Upside

Initiated

08/08/24

Replimune Group initiated with a Buy at Rodman & RenshawReplimune Group initiated with a Buy at Rodman & Renshaw

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Replimune Group

1 Month

xxx

Success Rate

16/20 ratings generated profit

Average Return

+5.59%

reiterated a xxx

rating 20 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +5.59% per trade.

3 Months

xxx

Success Rate

9/14 ratings generated profit

Average Return

+9.78%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +9.78% per trade.

1 Year

Peter LawsonBarclays

Success Rate

14/21 ratings generated profit

Average Return

+8.87%

reiterated a buy rating 19 days ago

Copying Peter Lawson's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +8.87% per trade.

2 Years

xxx

Success Rate

12/21 ratings generated profit

Average Return

-1.02%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of -1.02% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

REPL Analyst Recommendation Trends

Rating

Jan 25

Feb 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, REPL has received 16 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. REPL average Analyst price target in the past 3 months is 22.00.

Each month's total comprises the sum of three months' worth of ratings.

REPL Financial Forecast

REPL Earnings Forecast

Next quarter’s earnings estimate for REPL is -$0.83 with a range of -$0.92 to -$0.69. The previous quarter’s EPS was -$0.82. REPL beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.06% of the time in the same period. In the last calendar year REPL has Outperformed its overall industry.

No data currently available

REPL Sales Forecast

Next quarter’s sales forecast for REPL is $1.58M with a range of $0.00 to $7.90M. The previous quarter’s sales results were $0.00. REPL beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.52% of the time in the same period. In the last calendar year REPL has Preformed in-line its overall industry.

REPL Stock Forecast FAQ

What is REPL’s average 12-month price target, according to analysts?

Based on analyst ratings, Replimune Group Inc’s 12-month average price target is 22.00.

What is REPL’s upside potential, based on the analysts’ average price target?

Replimune Group Inc has 100.55% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is REPL a Buy, Sell or Hold?

Replimune Group Inc has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Replimune Group Inc’s price target?

The average price target for Replimune Group Inc is 22.00. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $31.00 ,the lowest forecast is $16.00. The average price target represents 100.55% Increase from the current price of $10.97.

What do analysts say about Replimune Group Inc?

Replimune Group Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of REPL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Replimune Group (REPL) Stock Forecast & Price Target

REPL Analyst Ratings

REPL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Replimune Group

REPL Analyst Recommendation Trends

REPL Financial Forecast

REPL Earnings Forecast

REPL Sales Forecast

REPL Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts